tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KYTX Stock Latest News

Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases
RatingsKyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases
8h ago
KYTX
Kyverna Therapeutics: Promising Clinical Progress and Strategic Execution Support Buy Rating
PremiumRatings
Kyverna Therapeutics: Promising Clinical Progress and Strategic Execution Support Buy Rating
11d ago
KYTX
Kyverna Therapeutics: Strategic Advancements and Financial Stability Underpin Buy Rating
PremiumRatings
Kyverna Therapeutics: Strategic Advancements and Financial Stability Underpin Buy Rating
11d ago
KYTX
Kyverna Therapeutics Reports Increased Losses Amid R&D Focus
PremiumCompany Announcements
Kyverna Therapeutics Reports Increased Losses Amid R&D Focus
12d ago
KYTX
Kyverna Therapeutics reports Q3 EPS (85c), consensus (95c)
PremiumThe Fly
Kyverna Therapeutics reports Q3 EPS (85c), consensus (95c)
12d ago
KYTX
KYTX Earnings this Week: How Will it Perform?
PremiumPre-EarningsKYTX Earnings this Week: How Will it Perform?
14d ago
KYTX
Kyverna Therapeutics Secures $150 Million Loan Facility
Premium
Company Announcements
Kyverna Therapeutics Secures $150 Million Loan Facility
21d ago
8K
KYTX
Kyverna Therapeutics secures up to $150M in non-dilutive financing
Premium
The Fly
Kyverna Therapeutics secures up to $150M in non-dilutive financing
21d ago
KYTX
3 Best Stocks to Buy Now, 10/30/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 10/30/2025, According to Top Analysts
25d ago
KYTX
OPRA
Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101
PremiumRatings
Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101
25d ago
KYTX
Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
PremiumThe Fly
Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
25d ago
KYTX
Kyverna Therapeutics’ KYV-101 Shows Promising Phase II Results in gMG, Supporting Buy Rating
PremiumRatings
Kyverna Therapeutics’ KYV-101 Shows Promising Phase II Results in gMG, Supporting Buy Rating
26d ago
KYTX
Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
PremiumThe FlyKyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
26d ago
KYTX
Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data
Premium
Company Announcements
Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data
26d ago
8K
KYTX
Kyverna Therapeutics Reports Positive Phase 2 Trial Results
Premium
Company Announcements
Kyverna Therapeutics Reports Positive Phase 2 Trial Results
26d ago
8K
KYTX
Kyverna Therapeutics announces data from Phase 2 from KYSA-6 clinical trial
PremiumThe Fly
Kyverna Therapeutics announces data from Phase 2 from KYSA-6 clinical trial
26d ago
KYTX
Kyverna Therapeutics Advances CAR T-Cell Therapy Study for Myasthenia Gravis
PremiumCompany Announcements
Kyverna Therapeutics Advances CAR T-Cell Therapy Study for Myasthenia Gravis
28d ago
KYTX
Kyverna Therapeutics Advances with Promising CAR-T Therapy for Stiff Person Syndrome
PremiumCompany Announcements
Kyverna Therapeutics Advances with Promising CAR-T Therapy for Stiff Person Syndrome
28d ago
KYTX
Kyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy
PremiumCompany Announcements
Kyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy
28d ago
KYTX
Kyverna Therapeutics’ Promising Clinical Data and Market Potential Justify Buy Rating
PremiumRatingsKyverna Therapeutics’ Promising Clinical Data and Market Potential Justify Buy Rating
28d ago
KYTX
Mitchell Kapoor’s Buy Rating on Kyverna Therapeutics Driven by Increased Confidence in KYV-101 for Myasthenia Gravis and Raised Approval Probability
Premium
Ratings
Mitchell Kapoor’s Buy Rating on Kyverna Therapeutics Driven by Increased Confidence in KYV-101 for Myasthenia Gravis and Raised Approval Probability
28d ago
KYTX
Kyverna Therapeutics price target raised to $20 from $10 at H.C. Wainwright
Premium
The Fly
Kyverna Therapeutics price target raised to $20 from $10 at H.C. Wainwright
28d ago
KYTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >